Dr. Grace Dy speaks to ecancer about the long-term outcomes with sotorasib in pretreated KRASp.G12C-mutated NSCLC. Dr Dy discusses the results from the 2-year analysis of CodeBreaK100. The pooled phase 1/2 CodeBreak 100 trial enrolled a total of 174 patients with locally advanced or metastatic KRAS G12C–mutant solid tumours.
Patients had received at least 1 prior systemic therapy or were ineligible or intolerant for treatment.
Those with stable brain metastases were permitted. In the trial, study participants received oral sotorasib at the FDA-approved dose, which was 960 mg once daily, until disease progression. Radiographic scans were done every 6 weeks up to week 48 and then once every 12 weeks thereafter.
Dr explains the results from this trial and talks about the impact these results can have on the future treatment of NSCLC.